Fig. 6

UCMSCs-Tandab(IL-6/CD20) inhibited the proliferation of SU-DHL-2/4. (A-B) CCK-8 assay to detect the toxicity effective of different E/T values (0:1, 0.1:1, 1:1, 10:1) on SU-DHL-2 (A) or SU-DHL-4 (B) cells. The solid lines indicate the groups treated with the supernatants of UCMSCs-Tandab(IL-6/CD20). n = 6 for each group. (C-F) EDU assay to evaluate the cell viability of SU-DHL-2 or SU-DHL-4 after different treatments (UCMSCs-Tandab(IL-6/CD20), UCMSCs-Vector, UCMSCs, Rituximab, Tocilizumab, mixture of Rituximab and Tocilizumab) with (E–F) or without (C-D) the presence of PBMCs and analytical results of positively stained EDU-positive cells to detect the percentage of proliferating cells after cell cultured for 72 h in (D) and (F). n = 5 for each group. ns: not significant, *p < 0.05, **p < 0.01